aTyr Pharma, Inc.(US:ATYR) Globenewswire·2025-10-31 18:24Core Viewpoint - A new class action lawsuit has been filed against aTyr Pharma, Inc. and its executives, expanding the alleged class period for investors who suffered losses due to misleading statements about the drug Efzofitimod [1][2]. Group 1: Class Action Details - The new class action, King v. aTyr Pharma Inc., covers investors who acquired aTyr securities from November 7, 2024, to September 12, 2025, significantly extending the previous class period that began in January 2025 [2][4]. - The lawsuit alleges that aTyr and its executives made false statements regarding the efficacy of Efzofitimod, leading to inflated stock prices [4][7]. Group 2: Allegations and Study Findings - The allegations center around aTyr's Phase 3 study, EFZO-FIT, which aimed to evaluate Efzofitimod's effectiveness in reducing steroid dependency in patients with pulmonary sarcoidosis [5][6]. - Throughout the class period, aTyr executives reportedly expressed confidence in the study's design while allegedly concealing adverse facts about the drug's efficacy [6][7]. Group 3: Market Reaction and Investigation - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, resulting in a dramatic stock price drop from $6.03 to $1.02, an 83.2% decline in one day [8][9]. - Hagens Berman is investigating whether aTyr misled investors regarding the drug's data and trial design, emphasizing its potential multi-billion-dollar market opportunity [10].